Piramal Pharma Reports ₹326 Cr FY26 Net Loss as Revenue Dips 3%

Piramal Pharma's consolidated revenue for FY26 declined 3% year-over-year to ₹8,869 Cr. The company reported a net loss of ₹326 Cr, a reversal from a ₹91 Cr profit in FY25, largely due to an exceptional impairment loss.

Key Financials for FY26

Piramal Pharma Ltd. reported a consolidated net loss of ₹326 Cr for the fiscal year ended March 31, 2026. This marks a significant reversal from the ₹91 Cr profit recorded in the previous fiscal year (FY25).

Consolidated revenue from operations saw a 3% year-on-year decline, settling at ₹8,869 Cr for FY26, down from ₹9,151 Cr in FY25.

An exceptional item, an impairment loss of ₹196 Cr on intangible assets under development, significantly impacted the company's profitability.

EBITDA for the fiscal year fell by 28% to ₹1,135 Cr, reflecting the combined effect of lower revenues and the exceptional charge.

Impact of Financial Results

The financial results highlight a challenging year for Piramal Pharma, with increased losses and reduced revenue, signalling pressure on its core operations.

The impairment loss on intangible assets indicates challenges with the commercial viability or valuation of certain development projects, prompting questions about asset management and future growth.

However, the company's management expresses optimism, pointing to growth momentum and strategic acquisitions like Kenalog® as catalysts for future performance.

Company History and Strategy

Piramal Pharma Limited was established in 2020 and demerged from Piramal Enterprises Limited, listing independently on Indian stock exchanges in October 2022. This strategic move aimed to create focused entities in pharmaceuticals and financial services.

In January 2026, the company strengthened its Complex Hospital Generics (CHG) portfolio by acquiring Kenalog® and associated brands from Bristol-Myers Squibb for $100 million, a move intended to broaden its product offerings in this segment.

In November 2024, SEBI cleared Piramal Pharma of past allegations related to listing and disclosure requirements stemming from Piramal Enterprises' tenure. These events, including an NGT penalty and a plant closure, were either deemed immaterial or occurred before PPL's existence.

Key Considerations for Investors

• Shareholders will need to assess the long-term impact of the impairment loss on future asset realization and profitability.
• The successful integration and performance of the newly acquired Kenalog® brands will be crucial for boosting the CHG segment.
• Management's ability to translate business momentum into revenue growth and cost efficiencies will be key to returning to profitability in FY27.
• Increased focus will be on the execution of growth strategies across the CDMO, CHG, and Consumer Healthcare segments.

Potential Risks

• Environmental Violations: Piramal Pharma has moved the Supreme Court challenging a Gujarat Pollution Control Board order for the closure of its Dahej manufacturing unit over alleged environmental violations, alongside contesting the encashment of a bank guarantee.
• Profitability Reversal: The significant net loss and decline in EBITDA underscore the pressure to improve operational performance and manage costs effectively.
• Intangible Asset Valuation: The substantial impairment loss raises concerns about the accuracy of valuations for assets under development and the potential for future write-downs.

Industry Context and Peers

Key Indian CDMO peers like Syngene International, Divi's Laboratories, Sai Life Sciences, and Laurus Labs operate in a sector projected for strong growth, driven by global outsourcing trends. While these peers navigate market dynamics, Piramal Pharma's financial setback, particularly the impairment loss, presents specific challenges. The industry growth trajectory is strong, but execution and managing specific business segment performance are critical.

Financial Snapshot

• Net Debt stood at ₹4,140 Cr as of March 2026.
• Consumer Healthcare e-commerce sales grew by 48% in FY26, now representing 27% of the segment's total sales.

What to Watch Ahead

• Monitor management commentary and performance metrics for FY27, focusing on revenue growth drivers and margin improvement strategies.
• Observe the financial contribution and integration success of the acquired Kenalog® brands within the CHG segment.
• Track the progress of the Supreme Court case regarding the Dahej manufacturing unit closure order.
• Assess the company's ability to recover biopharma funding trends and their impact on CDMO order inflows for FY27.
• Evaluate efforts to improve operational efficiencies and reduce costs across all business segments.